Transcript of Indoco Remedies’ Q3 FY26 earnings call shows emerging markets up 26.8% and API up 24%, Europe approvals delays remain, and cost control targeted at INR 150 crore excluding onetime items; nonrecurring costs were about INR 8–9 crore.
AI Assistant
Indoco Remedies Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.